Cases, hospitalizations and deaths due to COVID-19 have been increasing since mid-September in BC and as of January 2021 remain elevated. Two mRNA vaccines have been authorized for use in Canada but vaccine supply will be limited through the first quarter of 2021, requiring strategic management to address scarcity during a period of heightened need. To extend protective vaccine coverage to as many priority group members as possible, population risk assessment and response require consideration of second dose deferral. This talk will review the evidence and benefit-risk analysis underpinning decisions to defer the second dose of COVID-19 vaccine.

Video here https://nexuswebcast.mediasite.com/Mediasite/Showcase/bc-cdc-showcase/Presentation/3b71312f7bbc438ea0cfc65408e552f21d

Leave a Reply

Your email address will not be published. Required fields are marked *